



Express Mail No.: EV 335 856 304 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Bennett *et al.*

Confirmation No.: 6892

Application Serial No.: 09/642,557

Group Art Unit: 1626

Filed: August 18, 2000

Examiner: S. Wright

For: PYRAZOLOANTHRONE AND  
DERIVATIVES THEREOF AS JNK  
INHIBITORS AND COMPOSITIONS  
AND METHODS RELATED  
THERE TO

Attorney Docket No.: 10624-046-999

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56 and 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **CD-CH**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." A copy of references **CD-CH** is enclosed.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review each of the references identified on the attached Form PTO-1449, and that the references be made of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. §1.97(c), this Second Supplemental Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. §1.97(b) but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, and pursuant to 37 C.F.R. §1.97(c)(2) is accompanied by the fee set forth in §1.17(p) estimated to be \$180.00. Accordingly, please charge the required fee of \$180.00 to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this document is enclosed for accounting purposes.

Date July 29, 2003

Respectfully submitted,

*Anthony M. Insogna, N.Y. No. 35,203*  
*By: Matthew E. Lutz, N.Y. No. 36,343*  
35,203

Anthony M. Insogna

(Reg. No.)

**PENNIE & EDMONDS** LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT



## U.S. PATENT DOCUMENTS

ATTY DOCKET NO.	10624-046-999	APPLICATION NO	09/642,557
APPLICANT		Bennett et al.	
FILING DATE	August 18, 2000	GROUP	1626

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**OTHER REFERENCES (Including Author, Title, Date, Page, Pertinent Pages, Etc.)**

CF	Spiegelman et al., "Regulation of Adipocyte Gene Expression in Differentiation and Syndromes of Obesity/Diabetes", <i>J. of Biol. Chem.</i> 268:6823-6826 (1993).
CG	Hirosumi et al., "A central role for JNK in obesity and insulin resistance", <i>Letters to Nature</i> 420:333-336 (2002).
CH	Showalter et al, "Design, Tumor Biology, and Biochemical Pharmacology of Anthrapyrazoles" <i>Bioact. Mol. Chapter VI:201-243</i> (1988).

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.